Cure Today19h
Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for ...
Merck Races to Launch Subcutaneous Keytruda Amid Looming Patent Expiry for IV Version
Merck accelerates subcutaneous Keytruda rollout to protect cancer drug's dominance as IV patent nears 2028 expiry.
Cure Today15h
Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple ...